Tufts CSDD data shows no outsourcing model wins on speed or quality. Executive Director Ken Getz explains what matters more.
- What Happens When Acquisition Due Diligence Ignores Clinical Operations?
- Who's Wearing The Patient Recruitment Hat When Your Trial Decisions Are Made?
- Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Two Parallel Trials, A Potential New Option For Protection From COVID-19
- Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
GUEST COLUMNISTS
-
Firsthand Findings: How Incannex Is Designing Trials That Support Regulatory Approval
Incannex CEO Joel Latham explains how thoughtful trial design and dose optimization can turn promising data into an approval-ready strategy.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Lupus Researchers Now Have A Three-Pillar RWD Platform To Support Discovery And Development
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Novel Science, Familiar Regulatory Pathways: Inside Tonix's Clinical Development Strategy
Tonix CEO Seth Lederman, MD, explains how the company pairs novel science with proven regulatory paths across fibromyalgia, depression, and Lyme disease.
-
As U.S. Trial Share Slips, A Coalition Maps A Path To Broader Patient Access
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
A Window Into Aging: Why Skin Is the First Test For RLS-1496
Rubedo’s Marco Quarta explains how patient selection, controls, biopsies, and biomarkers shaped early RLS-1496 trial protocols.
-
Brazil's Regulatory Transformation: Building And Supporting Sites Beyond The AMCs
Our expert chat about Brazil’s clinical research transformation concludes with SBOC President-elect Fabio Franke, who explores building sustainable trial capacity beyond the country’s major AMCs.
-
Brazil's Regulatory Transformation: Expanding Clinical Trial Participation
A discussion of Brazil’s clinical research transformation continues as this Q&A series turns to Maiko L. Tonini, Ph.D., of Brazil’s Ministry of Health, to explore expanding clinical trial participation.
CLINICAL TRIAL WHITE PAPERS
-
Global Trial Disclosure Landscape Grows Increasingly Complex
The industry is witnessing a global trend toward increased transparency and more stringent enforcement of clinical trial reporting requirements. However mechanisms and penalties differ significantly across regions and countries.
-
The Evolving Landscape Of Emerging Biopharma: Modern Trends And Flexible Trial Designs9/28/2026
Running complex trials on a lean budget? See how adaptive designs, decentralized models, and early real-world evidence help emerging drug developers plan globally and get therapies to patients faster.
-
Biopharma Reaping Numerous Benefits From AI2/18/2026
Multiple AI use cases with significant impact have been identified, and they are expected to drive innovations in clinical trials, precision medicine, and commercial operations.
-
Wearables For Optical Cardiovascular Monitoring6/10/2025
Wearable digital health technologies (DHTs) are transforming cardiovascular health monitoring by enabling continuous, real-world assessment through optical sensors like photoplethysmography (PPG).
-
Redefining Vaccine Trial Recruitment8/8/2026
Modern vaccine trials demand flexible, transparent recruitment workflows. Discover strategies to overcome enrollment delays and build representative, diverse study cohorts.
-
Navigating Adverse Immunostimulation: A Practical Guide For Clinical Researchers9/30/2025
Explore a systematic approach to evaluate adverse immunostimulation (AIS) in drug development through standardized biomarker sampling and tailored management strategies.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Overcoming Unexpected Obstacles In A Phase 1 Study1/29/2025
Discover how the implementation of mobile vision clinics (MVCs) was used to enhance efficiency in a Phase 1 clinical trial.
-
Optimizing Chronic Cough Phase 3 Trials With Point-Of-Need Eye Assessments1/15/2025
Collaboration was key for Company W to overcome challenges with an FDA-mandated ocular substudy, including limited resources for ocular assessments and logistical difficulties
-
Focusing On Mature Assessments Of Physical Activity And Function11/17/2026
Obesity trials need more than the scale. See how wearable sensors can track physical function and sleep as trusted endpoints, with little extra burden on patients.
-
Accelerating Early Phase Oncology Study Development4/17/2025
Explore a close collaboration to co-develop a comprehensive, adaptive protocol designed to support key decisions across multiple trial phases for an innovative cancer therapy.
-
Improving Clinical Trial Label Translation Through Centralized Reuse And Control8/10/2026
Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.
-
Redefining Accessibility For Pediatric Patients9/24/2025
Explore how meeting patients where they are can redefine what successful pediatric trial delivery looks like.
NEWSLETTER ARCHIVE
- 11.20.26 -- Oversight Monitoring In Clinical Trials
- 11.20.26 -- Overloaded Sites, Stalled Enrollment, Lost Patients: Where Trial Execution Breaks Down
- 11.19.26 -- A New Era For Clinical Development For Brazil
- 11.18.26 -- Lab Logistics: Delivering The Complex Without Compromise
- 11.18.26 -- Sponsors Can Drown In Data As Patient Diversity Gaps Persist
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
Recruitment problems can start long before actual recruitment. Who is making sure your team gets ahead of those challenges?
-
Lupus Nexus unites a registry, biorepository, and data exchange to give researchers longitudinal real-world data without building the infrastructure from scratch.
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
FOCUS ON PATIENTS
-
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Clinical trial patients may need care outside of the trial protocol. Discover how closing information gaps can protect safety, trial participation, and data integrity.
-
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
EDITORIAL COLLECTIONS
Take a deep dive into the issues shaping clinical research today with our curated Editorial Collections. Each collection features expert insights and practical strategies addressing today’s biggest challenges in clinical trial planning and execution.
More Editorial Collections
